Amckaus registers Phase 2 trial of Aom0304 for hypertrophic cardiomyopathy
A newly listed study will test multiple doses of Aom0304 in obstructive and non-obstructive HCM patients ahead of planned Phase 3 development.
This week's update covers a single newly registered trial for Amckaus PTY LTD.
- Aom0304, an oral drug given as an enteric coated capsule, is entering a Phase 2 study (NCT07675668) for adults with symptomatic hypertrophic cardiomyopathy, covering both obstructive (oHCM) and non-obstructive (nHCM) forms. The trial is meant to characterize the safety, tolerability, efficacy, and pharmacokinetics of Aom0304 across oHCM and nHCM populations and to help select doses for future Phase 3 development.1 The study is listed as not yet recruiting, with an estimated enrollment of 56 participants1 and an estimated start date of October 1, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.